Skip To Main Content
Oriella Stellakis on Muck Rack

Oriella Stellakis

As seen in: British Pharmacological Society
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Oriella

Contact Oriella, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ACKR1 /Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)

|
By Stephen Murtough, Daisy Mills, Oriella Stellakis
| British Pharmacological Society
1 BACKGROUND AND OVERVIEW Clozapine is the only licenced medicinal product for treatment-resistant schizophrenia.1-6 This refers to people who have not responded to two or more antipsychotic drugs (including at least one second-generation antipsychotic).1, 4, 7 Approximately 30% of people with schizophrenia are treatment resistant,8 and they have an increased risk of hospitalization and suicide.9 When compared with other antipsychotic drugs, clozapine is the most effective therapy for...
Open in Who Shared Issue with article?
See all 1 articles